SCHEDULE: Cargo Therapeutics: Tang Capital Completes Merger

Tang Capital reports the completion of a merger with Cargo Therapeutics through Concentra Merger Sub VII, resulting in Cargo Therapeutics becoming a wholly-owned subsidiary of Concentra Biosciences.

Summary

• This is Amendment No. 2 to the Schedule 13D filed on February 21, 2025, and amended on July 9, 2025.
• The Offer by Merger Sub for all of the Issuer's Common Stock commenced on July 21, 2025.
• On August 19, 2025, the Offer expired, and Merger Sub accepted 34,569,840 shares, representing approximately 71.48% of the total shares issued and outstanding.
• Merger Sub merged with and into the Issuer on August 19, 2025, with the Issuer surviving as a wholly-owned subsidiary of Concentra.
• Each share of common stock of Merger Sub was converted into the right to receive the Offer Price.
• As of the date hereof, the Reporting Persons beneficially own an aggregate of 10,000 shares of the Issuer's Common Stock, representing 100% of the outstanding shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive, reflecting the successful completion of a planned merger. While it means the end of Cargo Therapeutics as a public entity, it signifies a strategic move for Concentra Biosciences.

Positives

• Completion of the merger provides clarity and finality to the transaction.
• Concentra Biosciences now wholly owns Cargo Therapeutics, potentially streamlining operations and strategic alignment.

Negatives

• None explicitly stated in the filing, but the completion of the merger means Cargo Therapeutics is no longer a publicly traded entity.

Risks

• None explicitly stated in this filing.

Future Outlook

The Issuer will continue as a wholly-owned subsidiary of Concentra Biosciences, LLC.

Industry Context

This merger reflects ongoing consolidation trends within the biotechnology and pharmaceutical industries, where larger entities acquire smaller companies to expand their pipelines or technologies.

Comparison to Industry Standards

• Comparable transactions include acquisitions of smaller biotech firms by larger pharmaceutical companies to bolster their drug development pipelines.
• The structure of the merger, utilizing a tender offer followed by a merger pursuant to Section 251(h) of the Delaware General Corporation Law, is a common approach in acquisitions of publicly traded companies.

Stakeholder Impact

• Shareholders who tendered their shares received the Offer Price.
• Employees of Cargo Therapeutics will now be part of Concentra Biosciences.
• Customers and partners of Cargo Therapeutics will likely see changes as the company integrates into Concentra's operations.

Key Dates

Recommendation

The merger is complete, and Cargo Therapeutics is no longer a publicly traded company. Therefore, a hold recommendation is appropriate for those who tendered their shares and received the offer price.

Keywords

Merger, Cargo Therapeutics, Concentra Biosciences, Tang Capital, Schedule 13D, Acquisition